Skip to content Skip to footer
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

10 articles published Follow:
MadeAi

MadeAi™ Unveils New Capabilities for GVD and JCA Reporting, Setting a New Benchmark for Life Science GenAI-Enabled Evidence Synthesis and Reporting

MadeAi Press Release10 November 202576Views0Likes0Comments
GLASGOW, SCOTLAND and CAMBRIDGE, MA, USA  November 10, 2025—At ISPOR Europe 2025 today, MadeAi™, the GenAI-powered evidence synthesis and report generation platform for life sciences, announced the launch of new capabilities designed to streamline and accelerate global value dossier (GVD) and Joint Clinical Assessment (JCA) submissions. With these advancements, MadeAi delivers the most comprehensive, AI-native…

Read More

Real-Life Science

From Idea to Impact: AI Use Cases That Delivered Real-Life Science Business Results

Thought Leadership7 October 2025194Views0Likes0Comments
Introduction Artificial Intelligence is redefining healthcare and life sciences. From improving patient care to accelerating drug discovery, AI is proving to be more than just a technological trend; it’s a critical enabler of innovation and efficiency. In this article, we explore real-world AI applications in clinical studies, pharmacovigilance, diagnostics, and medical operations. These use cases…

Read More

AI in Evidence Generation

How HTA Agencies Are Evaluating AI in Evidence Generation

Thought Leadership8 September 2025201Views0Likes0Comments
As AI rapidly reshapes the evidence landscape, health technology assessment (HTA) bodies are beginning to define clear expectations for its use in submissions. At CapeStart, we work closely with life sciences clients navigating these changes—especially those integrating GenAI into literature reviews, RWE generation, economic modeling, Joint Clinical Assessment (JCA) support, Clinical Evaluation Reports (CERs), Patient…

Read More

ROI of GenAI

How MadeAi™ Uses GenAI-Aided Review & AI as Reviewer to Beat Manual SLR Solutions

Thought Leadership6 August 2025149Views0Likes0Comments
In today’s fast-paced life sciences environment, literature reviews are critical—but they’re also time-consuming, labor-intensive, and increasingly expected to support regulatory, HEOR, and market access submissions while maintaining full transparency and traceability.  While traditional platforms offer useful automation features, most are either rules-based classifiers or structured workflow tools, limiting their adaptability and explainability. That’s where MadeAi™…

Read More

Literature Review

How to Evaluate GenAI-enabled Literature Review Platforms: A Buyer’s Guide to Transparency, Accuracy, and Compliance

Thought Leadership23 July 2025317Views0Likes0Comments
The rise of generative AI (GenAI) is transforming how life sciences organizations approach evidence synthesis, regulatory submissions, and market access activities. As literature review workflows become more complex—and timelines more compressed—life science professionals are increasingly turning to GenAI-enabled platforms to streamline systematic literature reviews (SLRs), reduce manual burden, and scale evidence synthesis. However, evaluating…

Read More